NCT01519349View on ClinicalTrials.gov

Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Becker Muscular DystrophySporadic Inclusion Body Myositis
Interventions
BIOLOGICAL

rAAV1.CMV.huFollistatin344

"* First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)~* Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)~* Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)"

Trial Locations (1)

43205

Nationwide Children's Hospital, Columbus

All Listed Sponsors
collaborator

Parent Project Muscular Dystrophy

OTHER

lead

Nationwide Children's Hospital

OTHER

NCT01519349 - Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis | Biotech Hunter | Biotech Hunter